Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062322 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00062322 is a Phase 1 study that has completed, run by Fox Chase Cancer Center.
The verdict
NCT00062322, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Irinotecan and cisplatin may also make the tumor cells more sensitive to radiation therapy. Combining chemotherapy with radiation therapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: This phase I trial is studying the side effects of neoadjuvant radiation therapy given together with irinotecan and cisplatin followed by surgery in treating patients with limited-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG irinotecan hydrochloride
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062322
The ClinicalTrials.gov registry entry for NCT00062322 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00062322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062322 about?
NCT00062322 is a clinical study titled "Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Irinotecan and cisplatin may also make the tumor cells more sensitive to radiation...
What is the current status of trial NCT00062322?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00062322?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), irinotecan hydrochloride (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00062322?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.